A5072819661- Acute Myeloid Leukemia Research
- Cancer, Lipids, and Metabolism
- Epigenetics and DNA Methylation
- Protein Degradation and Inhibitors
- Ferroptosis and cancer prognosis
- Sulfur Compounds in Biology
- Cancer Cells and Metastasis
- Histone Deacetylase Inhibitors Research
- Cancer-related gene regulation
- Glutathione Transferases and Polymorphisms
- Wnt/β-catenin signaling in development and cancer
- RNA modifications and cancer
University Medical Center Groningen
2023-2024
University of Groningen
2023-2024
Dialyse Centrum Groningen
2022-2023
University of Amsterdam
2021
Cysteine is a nonessential amino acid required for protein synthesis, the generation of antioxidant glutathione, and synthesizing nonproteinogenic taurine. Here, we highlight broad sensitivity leukemic stem progenitor cells to cysteine depletion. By CRISPR/CRISPR-associated 9-mediated knockout cystathionine-γ-lyase, cystathionine-to-cysteine converting enzyme, by metabolite supplementation studies upstream cysteine, functionally prove that not synthesized from methionine in acute myeloid...
Abstract Identification of specific and therapeutically actionable vulnerabilities, ideally present across multiple mutational backgrounds, is needed to improve acute myeloid leukemia (AML) patients’ outcomes. We identify stearoyl-CoA desaturase (SCD), the key enzyme in fatty acid (FA) desaturation, as prognostic patients' outcomes and, using clinical-grade inhibitor SSI-4, show that SCD inhibition (SCDi) a therapeutic vulnerability AML models vitro vivo. Multiomic analysis demonstrates SCDi...
ABSTRACT In the past forty years, WNT/CTNNB1 signaling pathway has emerged as a key player in mammary gland development and homeostasis. While also evidently involved breast cancer, much unclarity continues to surround its precise role tumor formation progression. This is largely due fact that specific direct effects of hyperactive on epithelium remain unknown. Here we use primary mouse organoid culture system close this fundamental knowledge gap. We show induces competing cell proliferation...
Abstract Identification of specific and therapeutically actionable vulnerabilities in acute myeloid leukaemia (AML) is needed to improve patients’ outcome. These features should be ideally present many patients independently mutational background. Here we identify de novo fatty acid (FA) desaturation, specifically stearoyl-CoA desaturase (SCD) inhibition, as a therapeutic vulnerability across multiple AML models vitro vivo . We use the novel clinical grade SCD inhibitor SSI-4 show that...